CeriBell (CBLL) vs CapsoVision (CV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CeriBell (CBLL) has outperformed CapsoVision (CV) over the past year, gaining 79.5% versus a gain of 16.8%. CeriBell is the larger company by market cap ($1.06 billion vs $327.6 million), about 3.2 times the size. CeriBell converts more of its revenue into profit, with a net margin of -60.0% versus -186.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBLL | CV |
|---|---|---|
| Share price | $27.39 | $6.11 |
| Market cap | $1.06B | $327.56M |
| 1-day change | +6.37% | -3.17% |
| YTD return | +24.90% | -42.84% |
| 1-year return | +79.49% | +16.83% |
| EPS (TTM) | $-1.95 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $89.06M | $13.55M |
| Revenue growth (YoY) | +36.09% | +15.29% |
| Net income (latest FY) | $-53.41M | $-25.32M |
| Gross margin | 87.89% | 52.92% |
| Operating margin | -65.57% | -188.25% |
| Net margin | -59.97% | -186.77% |
| 52-week high | $28.89 | $15.37 |
| 52-week low | $14.87 | $4.50 |
| Distance from 52-week high | -5.19% | -60.25% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.26% | +55.48% |
| Average volume | 452.64K | 173.59K |
| Shares outstanding | 38.84M | 53.61M |
| Employees | 327 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CeriBell is about 3.2 times larger than CapsoVision by market value ($1.06B vs $327.56M).
- CBLL has outperformed CV by 62.7 percentage points over the past year.
- CeriBell is more profitable, keeping -60.0 cents of every revenue dollar as net income versus -186.8 cents for CapsoVision.
- CeriBell grew revenue faster in its latest fiscal year (+36.09% vs +15.29%).
About CeriBell
CBLL stock →CeriBell, Inc. operates as a medical technology company in the United States.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees
About CapsoVision
CV stock →CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees
CBLL vs CV FAQ
Which is bigger, CeriBell or CapsoVision?
CeriBell (CBLL) is larger, with a market capitalization of $1.06B compared with $327.56M for CapsoVision (CV).
Which stock has performed better over the past year, CBLL or CV?
CBLL returned +79.49% over the past 12 months, compared with +16.83% for CV (price return, excluding dividends). Past performance does not predict future results.
Are CeriBell and CapsoVision in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.